ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Trials coming to its Annual Scientific Meeting (ASM), which will take place September 30 – October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.
Late Breaking Clinical Trials is an always-popular session where speakers present the results of new research in heart failure. Featured in back-to-back sessions on Sunday, October 2, Late Breaking Clinical Trials provides exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field.
Due to the quantity of remarkable trials submitted, two Late Breaking Clinical Trials Sessions will take place, with each session providing a deep dive into the latest rapidly evolving research in the field of heart failure.
The following trials will be presented in-person, via livestream, and OnDemand post-session:
Sunday, October 2 at 8:00 AM - 9:30 AM ET
Sunday, October 2 at 9:45 AM - 10:45 AM ET
Registration for the meeting is open and an advance program is available to download. Learn more about the meeting and register at hfsa.org/asm2022.
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.
Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@hfsa.org
SOURCE Heart Failure Society of America